98.93  -0.79 (-0.79%)		12-08 16:01
Open: 99.38 High: 99.66 Volume: 10,389,150		Pre. Close: 99.72 Low: 97.81 Market Cap: 248,631(M)

Short term
Mid term
Targets	6-month :	123.62	1-year :	144.38
Resists	First :	105.83	Second :	123.62
Pivot price	99.81
Supports	First :	91.11	Second :	82.01
MAs	MA(5) :	100.56	MA(20) :	97.61
	MA(100) :	86.57	MA(250) :	0
MACD	MACD :	3.4	Signal :	3.7
%K %D	K(14,3) :	57.9	D(3) :	65.6
RSI	RSI(14): 57.8
52-week	High :	105.83	Low :	73.3

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ MRK ] has closed above bottom band by 44.0%. Bollinger Bands are 51.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 16 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	99.78 - 100.59	100.59 - 101.14
Low:	96.11 - 97.02	97.02 - 97.62
Close:	97.75 - 99.15	99.15 - 100.09

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Mon, 08 Dec 2025
ASH: Merck mulls future of polycythemia program while Takeda takes phase 3 victory lap - Fierce Biotech

Mon, 08 Dec 2025
MCCC STEM students tackle third annual Merck Automation and Innovation Challenge - thereporteronline

Mon, 08 Dec 2025
Merck outbid three competitors in $9.2B acquisition of Cidara - Endpoints News

Mon, 08 Dec 2025
Merck’s Keytruda SC hit with German preliminary injunction - IAM Media

Mon, 08 Dec 2025
German court blocks Merck’s Keytruda SC after Halozyme injunction - The Pharma Letter

Mon, 08 Dec 2025
Jim Cramer on Merck: “The People Who Run This Company Are Not Idiots” - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Drug Manufacturers - General
Shares Out	2,480 (M)
Shares Float	2,480 (M)
Held by Insiders	0 (%)
Held by Institutions	80.3 (%)
Shares Short	27,630 (K)
Shares Short P.Month	26,700 (K)

EPS	7.55
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	20.84
Profit Margin	29.6 %
Operating Margin	40.7 %
Return on Assets (ttm)	13.7 %
Return on Equity (ttm)	39.4 %
Qtrly Rev. Growth	3.7 %
Gross Profit (p.s.)	20.16
Sales Per Share	25.89
EBITDA (p.s.)	12.7
Qtrly Earnings Growth	87 %
Operating Cash Flow	17,060 (M)
Levered Free Cash Flow	14,530 (M)

PE Ratio	13.08
PEG Ratio	0
Price to Book value	4.74
Price to Sales	3.81
Price to Cash Flow	14.38

Dividend	0.81
Forward Dividend	0
Dividend Yield	0.8%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.